PUBLICATION

Function of orthologous fibroblast growth factor 11 protein in angiogenesis and immunomodulatory after spinal cord injury

Authors
Zou, C., Chen, M., Zhao, Q., Wang, L., Ye, L., Meng, X., Li, X., Zuo, Y., Wang, Z.
ID
ZDB-PUB-251007-4
Date
2025
Source
International journal of biological macromolecules : 148106 (Journal)
Registered Authors
Keywords
Recombinant FGF11 protein, angiogenesis, inflammation
MeSH Terms
  • Angiogenesis
  • Animals
  • Disease Models, Animal
  • Fibroblast Growth Factors*/genetics
  • Fibroblast Growth Factors*/metabolism
  • Fibroblast Growth Factors*/pharmacology
  • Immunomodulation*
  • Macrophages/drug effects
  • Macrophages/metabolism
  • Mice
  • Neovascularization, Physiologic*/drug effects
  • Spinal Cord Injuries*/drug therapy
  • Spinal Cord Injuries*/immunology
  • Spinal Cord Injuries*/metabolism
  • Spinal Cord Injuries*/pathology
  • Zebrafish
  • Zebrafish Proteins*/genetics
  • Zebrafish Proteins*/pharmacology
PubMed
41052555 Full text @ Int. J. Biol. Macromol.
Abstract
Intracellular fibroblast growth factors (iFGFs) are emerging as promising therapeutic agents in tissue engineering and regenerative medicine. Although FGF11, a typical iFGF, plays crucial roles in cellular hypoxia adaptation, its roles in angiogenesis and immunomodulation post-spinal cord injury (SCI) remain poorly characterized. This study investigated four FGF11 orthologs: ZFgf11a/ZFgf11b from zebrafish (Danio rerio) and MFGF11a/MFGF11b from mouse (Mus musculus). In vitro, intracellularly delivered ZFgf11a and MFGF11b exhibited stronger pro-angiogenic effects compared to ZFgf11b or MFGF11a. In a contusive SCI model, treatment with ZFgf11a and MFGF11b loaded lipid nanoparticles enhanced angiogenesis and blood-spinal cord barrier integrity, accompanied by upregulation of VEGFA, CD31, and ZO-1. Additionally, ZFgf11a and MFGF11b revealed different immunomodulatory effects in vivo: ZFgf11a increased expression of GATA3 and Arg1 while decreasing TBX21 and iNOS in T cells and macrophages, whereas MFGF11b only suppressed expression of TBX21 and iNOS. Both orthologs conferred neuroprotection at 11 and 28 days post injury (dpi), but only ZFgf11a promoted obviously functional locomotor recovery. Mechanistic studies indicated that ZFgf11a and MFGF11b could modulate macrophage-driven immunity via STAT3/MYC/TBK1/NFκB signaling axis. These findings identify ZFgf11a as potent therapeutic candidates for SCI and other disorders involving vascular dysfunction and inflammatory responses.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping